Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.5 [0.33, 0.77]
1 study · 592 participants
Moderate